Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1,551 - 1,600 out of 6,656

Document Document Title
WO/1999/015166A1
The invention provides a solid implant comprising at least one parasiticidal compound having low aqueous solubility; and tabletting excipients including a bulking agent. Implants according to the invention are convenient to administer an...  
WO/1999/014225A1
A V-28-3M/acetone adduct which is an intermediate for V-28-3M useful as an antifungal agent; a process for producing the same; and a method for purifying V-28-3M. Crude V-28-3M is dissolved in acetone to yield a V-28-3M/acetone adduct wh...  
WO/1999/012944A2
The present invention is directed to novel compositions and their use in the treatment of inflammatory responses. Specifically, the invention is directed to novel synthetic oligosaccharide constructs and their use to block lymphocyte bin...  
WO/1999/012946A1
Disclosed are 9-hydrazone erythromycin and 9-azine erythromycin derivatives and the processes for making the same. The compounds are useful intermediates for conversion into 6-O-alkyl erythromycin. Also disclosed are the processes for co...  
WO/1999/012542A1
8a-Azalides are useful in the treatment and prevention of bacterial respiratory and enteric infections in livestock animals, particularly in cattle and swine.  
WO/1999/012552A1
9a-Azalides are useful in the treatment and prevention of bacterial respiratory and enteric infections in livestock animals, particularly in cattle and swine.  
WO/1999/012947A1
Novel multicyclic erythromycin compounds and pharmaceutically acceptable salts and esters thereof having antibacterial activity having formula (I), (II), or (III), compositions comprising a therapeutically effective amount of a compound ...  
WO/1999/011651A2
Novel multicyclic erythromycin compounds and pharmaceutically acceptable salts and esters thereof having antibacterial activity having a formula selected from the group consisting of (I), (II), (III), (IV) and (V), compositions comprisin...  
WO/1999/010360A1
Oligosaccharide derivatives which have higher homogeneity and more excellent antiulcerous effects than those of fucose and rhamnose polysaccharides and are represented by the following general formula: Y-OCH(CH¿2?NHR)¿2? wherein Y repr...  
WO/1999/009031A1
A compound of the formula (I), wherein: nuc is the residue of a nucleoside analogue bonded through its single hydroxy group on the cyclic or acyclic saccharide moiety, R¿1? is hydroxy, amino or carboxy; optionally having esterified/amid...  
WO/1999/008687A1
13-Deoxyanthracycline derivatives as non-cardiotoxic anthracycline derivatives and processes for preparing 13-deoxyanthracycline derivatives.  
WO/1999/007719A1
Disclosed is a prodrugs of the formula (I) where A is a sulfur or a selenium, and R is derived from a mono- di- or oligosaccharide. Also disclosed is a prodrug of the formulas (II); where A is sulfur or selenium, R' is derived from a sug...  
WO/1999/007721A1
An improved process for the preparation of the antiparasitic compound 25-cyclohexyl-22,23-dihydro-5-hydroxyiminoavermectin B1 monosaccharide from doramectine and intermediates therefor and crystalline solvates thereof.  
WO/1999/006057A1
A description is given of novel soya extracts having a defined ratio of soya saponins to glucoside isoflavones; processes for their production; and pharmaceutical compositions containing these extracts.  
WO/1999/006421A1
Compounds are disclosed which have formula (I) wherein R¿1?-R¿2? are each independently selected from the group consisting of: (a) a hydrogen atom; and (b) a lower alkyl group, straight or branched chain, having 1 to 8 carbon atoms; or...  
WO/1999/005156A1
This invention provides a process for preparing a compound of formula (I): wherein R?1¿ is H or a hydroxyimino-protecting group; R?2¿ is H, C¿1-4? alkyl or C¿1-4? alkoxy; R?3¿ is C¿1-8? alkyl, C¿2-8? alkenyl or C¿3-8? cycloalkyl;...  
WO1998051695A3
The invention provides novel erythromycin derivatives in which methyl groups on the macrolactone ring have been substituted with -H, -Et, and/or -OH. The invention also provides reagents such as isolated polynucleotides, vectors comprisi...  
WO/1999/004652A1
Drinks, foodstuffs or drugs which contain compositions containing as the major components arbutin, quercetin and pyrolatin prepared from foodstuffs and are usable for relieving and treating menstrual pain and constipation, reducing the b...  
WO/1999/003986A2
Modified PKS gene clusters which produce novel polyketides in an efficient system in a host cell or in a cell free extract are described. The novel polyketides result from the incorporation of diketides of formula (1) or (2), wherein A i...  
WO/1999/003849A1
Dibenzazole compounds having general structure (I) and (II), wherein R¿1?, R¿2?, R¿3?, R¿4?, R¿5?, R¿6? are independently H or a substituent which aids in solubility of the compound or which provides a linker arm for linking the co...  
WO/1999/002542A1
A pharmaceutical composition comprising a nucleotide analogue and one or more glass forming additives which is suitable for freeze drying.  
WO/1999/002541A2
Erythromycin A oxime; in anhydrous and stable form; in the form of a solvate with non-halogenated organic solvent; and in the form of a hemihydrate, processes for its productions; and their use in the production of a semi-synthetic macro...  
WO/1999/002162A1
A range is disclosed of purine derivatives (I) which can act as inhibitors of cyclin dependent kinases (CDKs) and which thereby c an provide useful therapeutic compounds for use in treatment of tumours or other cell proliferation disorde...  
WO1998049315A3
Combinatorial libraries of polyketides can be obtained by suitable manipulation of a host modular polyketide synthase gene cluster such as that which encodes the PKS for erythromycin. The combinatorial library is useful as a source of ph...  
WO1998051694A3  
WO/1999/000125A1
Compounds are disclosed which are represented by formula (I) as well as salts and hydrates thereof. Pharmaceutical compositions and methods of treatment are also included.  
WO/1999/000124A1
Compounds are disclosed which are represented by formula (I); as well as salts and hydrates, thereof, wherein in part: X represents CH¿2?, CHF, CF¿2?, C=CH¿2?, CHSR, CHCH¿3?, C=S or CHOR. Pharmaceutical compositions and methods of tr...  
WO/1998/058917A1
Compounds are disclosed which are represented by formula (I) as well as salts and hydrates thereof wherein in part: X represents CH¿2?, CHF, CF¿2?, C=CH¿2?, CHSR, CHCH¿3?, C=S, C=O or CHOR. Pharmaceutical compositions and methods of ...  
WO/1998/056800A1
The invention relates to compounds of formula (I), and to pharmaceutically acceptable salts thereof, wherein R?1�, R?2�, R?6� and X are as defined herein. The invention also relates to pharmaceutical compositions containing the com...  
WO/1998/056801A1
This invention relates to compounds of formula (1) and to pharmaceutically acceptable salts thereof. The compounds of formula (1) are potent antibacterial agents that may be used to treat various bacterial infections and disorders relate...  
WO/1998/056802A1
The invention relates to compounds of formula (1) and to pharmaceutically acceptable salts thereof. The compounds of formula (1) are antibacterial agents that may be used to treat various bacterial and protozoa infections. The invention ...  
WO/1998/055491A1
The present invention relates to a novel process for preparing the anticancer compound, etoposide, in the C-1'-$g(b) anomeric form, as well as a novel intermediate compound.  
WO/1998/055492A1
An industrializable process for preparing V-28-3M useful as an antifungal by methylating V-28-3 efficiently. The process comprises protecting the amino group of the amino sugar moiety of V-28-3 with a suitable protective group, methylati...  
WO/1998/054308A2
The rapamycin gene cluster is an example of a gene cluster which includes a gene (rapL) leading to the formation of a precursor compound (pipecolic acid, in this case) which is required for inclusion in the larger product (rapamycin) pro...  
WO/1998/054197A1
Novel multicyclic erythromycin compounds and pharmaceutically acceptable salts and esters thereof having antibacterial activity having formulae (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), or (XI), pharmaceutical composit...  
WO/1998/054196A1
$g(a)-glycosides of opiates have been found to possess interesting and valuable pharmacological properties, particularly analgesic properties. The invention provides a compound being a sugar derivative of a biologically active opiate com...  
WO/1998/052934A1
The present invention discloses a two-step method for the preparation of 8-C-$g(b)-D-[2'-O-(E)-cinnamoyl]glycopyranosyl-2-[2-hydroxy] propyl-7-methoxy-5-methylchromone (the '540 compound') from the readily available 5-methylchromone, Alo...  
WO/1998/052959A1
The invention concerns novel glycosylated ginkgolide derivatives, their application as medicines and pharmaceutical compositions containing them. It also discloses a method for preparing said derivatives. In formula (I), W, X, Y and Z re...  
WO/1998/051694A2
Polymerizable saccharide monomers are made by the reaction of a saccharose and a (meth)acrylate. Hydrophilic, hydrophobic and thermoreversible gels and foams are formed upon polymerization of the saccharide monomers. Hydrophilic sucrose ...  
WO/1998/051696A1
The invention relates to compounds of formula (I) and to pharmaceutically acceptable salts thereof, wherein R is as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula (I), method...  
WO/1998/051315A1
An articular rheumatism remedy which is an asialotrisaccharic moranoline derivative represented by general formula [I] or a pharmacologically acceptable salt thereof, wherein -A- represents -(CH�2?)�m?-, -(CH�2?)�n?-NR?e�-CO-O-...  
WO/1998/051695A2
The invention provides novel erythromycin derivatives in which methyl groups on the macrolactone ring have been substituted with -H, -Et, and/or -OH and the ethyl side-chain has been substituted with hydroxymethyl or dihydroxyxyclohexylm...  
WO/1998/049176A1
Water soluble glycoconjugated fluorescent labeling reagents comprised of a fluorescent dye, one or more sugar or carbohydrate residues that impart water solubility, and a reactive group that allows covalent attachment of the reagent to a...  
WO/1998/049315A2
Combinatorial libraries of polyketides can be obtained by suitable manipulation of a host modular polyketide synthase gene cluster such as that which encodes the PKS for erythromycin. The combinatorial library is useful as a source of ph...  
WO/1998/046618A1
A new morphine derivative of formula (I) having enhanced activity in the treatment of pain is of the form 1-(morphine-6-yl)-$g(b)-D-glucopyrano siluronic acid, and acid addition and metal salts, wherein the usual ethylenic bond between t...  
WO/1998/042720A1
Erythromycin A derivatives of general formula (I) (wherein R represents pyridyl, quinolyl, nitrophenyl or methoxyphenyl) or pharmaceutically acceptable salts thereof, having a patent antibacterial power against not only erythromycin-sens...  
WO/1998/041532A1
Erythromycin A oxime in the form of a dihydrate having a water content of 4 % to 6.5 %, a process for its production and its use as an intermediate in the production of semi-synthetic macrolides of the erythromycin type.  
WO/1998/041214A1
Preventive or therapeutic agents for ischemic reflow disturbances comprising asialotrisaccharic moranoline derivatives represented by general formula (I) or medicinally acceptable salts thereof, wherein -A- represents -(CH�2?)�m?-, -...  
WO/1998/040393A1
Novel mycaminosyltylonolide derivatives represented by general formula (I) or salts thereof, and drugs comprising the same, wherein X represents a hydroxyl group or a hydrogen atom; R represents -CH�2?SR?1� (wherein R?1� represents...  
WO/1998/040392A1
Erythromycin A derivatives represented by general formula (I) or pharmaceutically acceptable salts thereof having potent antibacterial activities not only on the known erythromycin-sensitive bacteria but also erythromycin-tolerant bacter...  

Matches 1,551 - 1,600 out of 6,656